# Private Sector PrEP Delivery Policy And Regulatory Landscaping In Sub-Saharan Africa

Cami Rencken, Jacinta Ifunanya Azie, Angela Yang, Carol Levin

March 2023



STRATEGIC ANALYSIS, RESEARCH & TRAINING CENTER Department of Global Health | University of Washington

### **PROJECT OVERVIEW**

**Motivation:** This work aims to assist the Bill & Melinda Gates Foundation in developing a more holistic view of the opportunity in using private pharmacies and clinics as an innovative delivery channel for PrEP and inform possible scale-up strategies.



### **Project Objectives & Aims**

**Project Objective:** Conduct a landscape assessment of regulatory and policy barriers to PrEP (oral and long-acting) delivery through private sector pharmacies and clinics across Sub-Saharan Africa.

**Aim 1:** Understand the landscape of existing national strategies, policies, and funding related to HIV prevention, including PrEP.

**Aim 2:** Describe the landscape of pharmacy services and capabilities related to, but not limited to, PrEP and contraceptive care.

**Aim 3:** Explore the public-private partnerships in key geographies and the existing delivery channels for health services.

### Background

**HIV** – 37.7 million adults and children are living with HIV/AIDS and the highest burden comes from sub-Saharan Africa (two-thirds). In 2020, about 1.5 million new infections occurred with estimated deaths of 680,000.

**PrEP** – PrEP is highly effective for HIV prevention (roughly 99%), and currently exists as either a pill, vaginal ring, or an injection. Currently, there is a lack of accessible and cost-effective delivery methods for PrEP. Pharmacies may be able to fill this gap given their increased privacy, user preference, shorter wait times, and diverse clientele. However, in some countries, pharmacists are not allowed to prescribe PrEP.

### **METHODS**

### SCOPING

### RESEARCH METHODS

### **Country Selection\***

- Number of people with HIV/AIDS
- Number of adolescents (10-19) with HIV/AIDS
- Number of women (15+) with HIV/AIDS
- Adult prevalence of HIV/AIDS
- Annual deaths from HIV/AIDS
- Catalyst Global results

#### **Research Questions**

- What is the burden of HIV/AIDS?
- What is the current availability of PrEP?
- What is the funding distribution for HIV/AIDS?
- What are the current pharmacy services and pharmacist capabilities?
- What are the delivery channels for health services and community-focused work?
- What are the existing public-private partnerships?

### DATA ANALYSIS SYNTHESIZE FINDINGS

### **Grey Literature**

Searched grey literature including but not limited to: National Strategic Frameworks (NSF) and Country Operational Plans (COP); Reports from WHO & MSF; PEPFAR & Global Fund documents; Global PrEP tracker; Country-specific drug guidelines.

### **Subject Matter Experts**

Contacted content and in-country experts, through email and ZOOM (Appendix 2).

### **Rapid Review of Published Literature**

Conducted PubMed/MEDLINE search with 6 unique search strings (Appendix 1). Identified 187 articles, of which 15 were of relevance after title and abstract screening.

# Organization of Findings

START CENTER

#### **Country Overview**

• HIV

#### Epidemiology

- PrEP Overview
- PrEP Landscape
  - Injectable PrEP
  - Key stakeholders
  - National strategies including PrEP

# \*Malawi, South Africa, and Kenya were excluded due to existing research in these countries

#### **Private-Public Partnerships**

- Private pharmacy
  - landscape
  - Pharmacists role in PrEP
    - Case studies

#### Summary


Barriers

Facilitators

# COUNTRY SPECIFIC FINDINGS

Tier	Country	Government contribution towards HIV prevention funding	Proportion of total HIV funding that goes towards prevention	Availability of multiple forms of PrEP	Presence of DREAMS	Presence of MOSAIC	Delivery channels for health services and community- focused work	Political will
1	Zimbabwe							
	Uganda							
	Eswatini							
2	Mozambique							
	Zambia							
	Nigeria							
3	Tanzania							
	Ghana							

Tiers were determined by the indicators, of which key variables are listed in the columns of the above table. We ranked tiers by the following: Burden of HIV/AIDS (Incidence Rate, Prevalence); Availability of PrEP (PrEP Presentation and Availability, Injectable PrEP and use of CAB-LA, Key Stakeholder Engagement, National Strategic Focus on PrEP); HIV Funding (Total Annual Funding, Sources of Funding for Treatment and Prevention, Share of Funding Allocated to Prevention and/or PrEP); Pharmacy Landscape and Pharmacist Capabilities (Number and Distribution of Pharmacies, Catalyst Global Rankings, Pharmacists Ability to Dispense and Prescribe); Public-Private Partnerships (Regulations Related to PrEP Approvals and Distribution, Private Supply Chain Logistics).



Women \*\*Maximizing Options to Advance Informed Choice for HIV Prevention

\*\*\*Catalyzing Access to New Prevention Products to Stop HIV



# **COUNTRY SPECIFIC FINDINGS**





**Prep LANDSCAPE** 





Burden of HIV: About 215,208 people are currently living with HIV. Prevalence and Incidence rate: currently stands at 27% and 1.4% respectively – the highest in the world. AGYW (15 -24yrs): most infected population with a prevalence rate of 14% as against 4.1% for males in the same age bracket. PrEP demand: is high amongst key with targets set to increase for new KP initiated PrEP from 2,328 in COP21 to 2,829 in COP22.	PrEP forms: Oral PrEP is currently in use in Eswatini with ongoing CAB LA studies. National strategic framework and COP22: Shows an increased political will to scale new PrEP products. Funding: GOE contributes largely towards its HIV programs, spending up to 11% of total HIV funds towards prevention. Eswatini is one of the few countries that spends an increased amount of its budget (38%) on HIV programs with largest investments in clinical care, testing and treatment support. PEPFAR contributes largely towards PrEP services and takes a portion of DREAMS funding in 12 districts.	MOSAIC*: Exists DREAMS**: Exists Other Channels: Veru Inc. has partnered with governments, donor agencies (including African countries) "to build successful reproductive and sexual health programs and policies that integrate [the] FC2 female condom"	Pharmacist Capabilities: Administer injections: Unknown Administer birth control injections: Unknown Dispense oral PrEP: Unknown Prescribe PrEP: Unknown Self-injectable Contraceptive: No Other Pharmacy Landscape: No relevant documentation of standardized registration and regulation process of private health providers and pharmacies.
Burden of HIV: About 2.1 million people are currently living with HIV. Prevalence and Incidence rate: currently stands at 6.4% and 0.2% respectively AGYW (15 -24yrs): most infected population with a prevalence rate of 5.0% as zagainst 2.4% for males in the same age bracket. PrEP demand: PrEP targets increased from 55,000 in COP21 to 90,012 new enrollees in COP22	PrEP forms: Oral PrEP is currently in use in Mozambique National strategic framework and COP22: Shows an increased political will to scale PrEP program in the country Funding: 12% from HIV programs goes into prevention. Overall, PrEP budget has increased by 38% from COP21 to COP22, with a higher increase in PrEP funding for commodities at 47%. They increased their health budget up to 20% in FY21 with PEPFAR being the largest 'vertical'-budget donor in Mozambique. PEPFAR and GF are the main sources of funds for the HIV response, accounting for approximately 83% of HIV expenditures.	MOSAIC*: No DREAMS**: Exists Other Channels: Project Last Mile: GPS and medicine storage partnership	Pharmacist Capabilities: Administer injections: No Administer birth control injections: No Dispense oral PrEP: Unknown Prescribe PrEP: No Self-injectable Contraceptive: Yes Other Pharmacy Landscape: The private health sector is regulated and both private and public facilities require licenses for operating.
Burden of HIV: About 1.3million people are currently living with HIV in Zambia Prevalence and Incidence rate: currently stands at 1.3% and 0.2% respectively AGYW (15 -24yrs): In 2021, over 40% of new HIV infections in Zambia occurred among AYP (15- 24) with AGYW bearing the greatest burden: AGYW	PrEP forms: Oral PrEP is currently in use in Zambia National strategic framework and COP22: Mentions PrEP and inclusion plans into programs through KPs and the DREAMS program. Funding: 8% of its HIV funds goes into Prevention services. Govt largest contributions in HIV programing is in Laboratory services and treatment monitoring	MOSAIC*: Exists DREAMS**: Exists Other Channels: Corridors of Hope 2014: Private pharmacists provide oral ART. For CIDRZ, 2024 proposing pilot distribution of PrEP through private pharmacies as a differentiated service delivery.	Pharmacist Capabilities: Administer injections: No Administer birth control injections: No, unless specially trained Dispense oral PrEP: No Prescribe PrEP: No Self-injectable Contraceptive: Yes Other Pharmacy Landscape: Private Pharmacies are major and trusted source of health information and services. Central Dispensing Units: dispensing activities are centralized

Pharmacist receives a stipend of USD \$75 per month, which is equivalent to the amount paid to a lay volunteer at the facility level.

and generally automated, but delivery/pick-up of medication occurs at lockers, informal retail outlets, churches, supermarkets, health facilities, or Community Pharmacies.

#### 1.3million peop currently living Zambia Prevalence an rate: currently

Zambia

**Aozambigue** 

respectively AGYW (15 -24 2021, over 40% infections in Za occurred amon 24) with AGYW greatest burden: AGYW comprise 78% of new infections for this growing

population. PrEP demand: Demand and initiations are high, but retention decreases to 12% after 12 months of initiation

services and treatment monitoring but PEPFAR and GF drives most of the funding for HIV and PrEP programs.



# **COUNTRY SPECIFIC FINDINGS** -





Prep Landscape

PrEP forms: PrEP is being



DREAMS\*\*: Does not exist

Between 2016 and 2019,

USAID's Sustainable Financing

establish ARV refill services at

117 private clinics and 320 private

pharmacies across four states in

Nigeria, enabling nearly 18,000

patients to pick up medication

closer to home: 95 percent of

patients picked up their refills on

time, and 93 percent of patients

were retained in the model after

Initiative provided funding to

MOSAIC\*: Exists

Other Channels:

one year.



**Pharmacist Capabilities:** 

Administer injections: Yes

are currently living with HIV in Nigeria **Prevalence and** Incidence rate: currently stands at 1.4% and 0.03% respectively AGYW (15 -24yrs): prevalence among AGYW (1.8%) is high when compared to men

Burden of HIV: About

over 1.8million people

(1.0%). PrEP demand: PrEP demand is high among KPs, and adolescents and young people (AYP)

Burden of HIV: About over 1.7million people are currently living with HIV in Tanzania **Prevalence and Incidence** rate: currently stands at

ligeria

4.7% and 0.3% respectively AGYW (15 -24yrs): prevalence among AGYW (2.28%) is high when compared to men (1.24%). PrEP demand: Frameworks indicates large

unmet need for PrEP in Tanzania and intentions to address this need through advocating for introductions of alternative PrEP options.

Burden of HIV: About over

currently living with HIV in

Prevalence and Incidence

347,370 people are

Ghana

offered as Oral PrEP TDF/XTC since 2020 Q3 with over 400K initiations as at Q3 2022 National strategic framework and COP22: Policy documents indicates focus on KPs and sero-discordant couples. Funding: PEPFAR, Global fund and GON are the main funders of HIV and prevention programs. Nigeria spends 4% of their HIV funds on prevention with PEPFAR contributing majorly for PrEP activities.

#### PrEP forms: PrEP is being MOSAIC\*: Does not exist offered as Oral PrEP TDF/XTC since 2020 Q3 with over 400K initiations as at Q3 2022 National strategic framework and COP22: Frameworks focus on advocating for more PrEP option for KPs and AGYW Funding: Domestic financing is a small fraction of the total needed amount for HIV funding, and disbursement does not meet budget levels. 14% of the total HIV funds is targeted towards prevention and is mostly

DREAMS\*\*: Exists Other Channels: Accredited Drug Dispensing Outlets (ADDO) established in 2003 to improve access to essential medicines and pharmaceutical services to population in rural and per-urban areas with no pharmacies (part II pharmacies, duka la dawa baridi (DLDB)). Tanzania is expanding PrEP services to private pharmacies (From CxOP 2022) PEPFAR/T will intensify distribution of HIVST in male-dominated workplaces, both public and private (as well as formal and informal) workplaces.

Administer birth control injections: No Dispense oral PrEP: Yes Prescribe PrEP: No Self-injectable Contraceptive: Yes **Other Pharmacy Landscape:** SHIPS Private/Public Partnerships in Abuja and Lagos (focused on testing and prevention). A baseline assessment in Nigeria found that 92 percent of CPs were willing to provide the services, more than 30 percent of clients were willing to access services at a CP, and up to 20 percent of clients were willing to pay the dispensing fee for ART

refills.

Administer injections: Unknown Administer birth control injections: Unknown Dispense oral PrEP: Yes, and the ring Prescribe PrEP: No Self-injectable Contraceptive: Yes Other Pharmacy Landscape: 2014 study: Many drug dispensers said that many pharmacies do not have rooms for counseling patients and clients, which affects confidentiality.

**Pharmacist Capabilities:** 

MOSAIC\*: Does not exist

DREAMS\*\*: Does not exist

**Other Channels:** 

WAAF, a private sector partner, was the first of the two EpiC partners to begin offering PrEP.

In August 2020, WAAF initiated the first individuals on daily PrEP at its on-site clinic in Accra, called the International Health Care Center (IHCC), as well as through its mobile clinics.

#### **Pharmacist Capabilities:**

Administer injections: Yes. COVID Administer birth control injections: No, although 97% of pharmacists dispense birth control injections Dispense oral PrEP: No Prescribe PrEP: Unknown Self-injectable Contraceptive: Yes

<u> Shana</u>

rate: currently stands at 1.67% and 0.6% respectively AGYW (15 -24yrs): 73.91% of adolescents and youths living with HIV are

females PrEP demand: Prevention focus indicates more interest in KPs mainly FSW and MSMs as a population with a large unmet need for PrEP.

PrEP forms: PrEP is being offered as Oral PrEP TDF/XTC National strategic framework and

contributed by GF and PEPFAR

COP22: Available frameworks indicates less focus on PrEP than ART. This is indicated by the percent of funds allocated by the govt on PrEP. Funding: Ghana improved health allocation from last budget but is still largely donor dependent with GF and PEPFAR being the main external HIV program funding channel. GF capped its commitment to fund the cost of commodities to a maximum of 125,000 PLHIV on treatment. As the number of PLHIV on treatment continues to increase, the cost of commodities supply will increase, which means the GoG will need to increase financial resources to pay for the additional supply needs.



# SUMMARY



Strong political will: 12% of all HIV funding is allocated towards prevention & fast PrEP approvals

Commitment to AGYW:Presence of MOSAIC and DREAMS

History of strong public-private partnerships

Limited pharmacist capabilities



Strong political will: 12% of all HIV funding is allocated towards prevention & CAB-LA is approved

\$

Commitment to AGYW:**Presence of MOSAIC and DREAMS**, ongoing research is focused on this population

Strong network of private pharmacies and engagement with the community

Limited pharmacist capabilities (this is expected to change soon)

# **ESWATIN**

**Strong political will:** 11% of all HIV funding is allocated towards prevention & ongoing CAB-LA studies exist




Commitment to AGYW:Presence of MOSAIC and DREAMS

History of strong public-private partnerships

Pharmacies face issues with the **supply chain and lack of standardization** of policies

### MOZAMBIQUE



Commitment to AGYW:Presence of MOSAIC and DREAMS

History of strong public-private partnerships

Limited pharmacist capabilities

ZAMBIA



8% of all HIV funding is allocated towards prevention

Commitment to AGYW:Presence of MOSAIC and DREAMS

Pharmacists can distribute ARTs and pharmacy delivery of PrEP is in the pipeline

Low community acceptance of PrEP



DSD are widespread and there is a strong private sector

Pharmacists currently deliver contraceptive injections and oral PrEP

Lack of regulation for pharmacies

**Only 4%** of all HIV funding is allocated towards prevention

No DREAMS programs



While 14% of HIV funding went towards prevention in 2022, this has been **decreasing** over the last 5 years

Has a DREAMS program but no MOSAIC

Weakness in **supply chain** and a large unmet need for oral PrEP

Have **self-injectable contraception** options

Pharmacies distribute self-testing kits

Limited DSD

No DREAMS or MOSAIC

Challenges with **sustainability** threaten HIV prevention and treatment





Tier 3

**INFORMATION GAPS** 

# Out-of-Date NSFs

PrEP became available after some NSFs were published. Current practices may not be represented in NSFs.

### Pharmacist Canabilities

Many countries do not have this information publicly available.

### Country Insights Conducting KIIs would validate and enhance findings for improved information on PrEP product availability, pharmacy capability, potential delivery channels and regulatory processes.

**START CENTER** 

\*

GHANA

### **APPENDICES**

# 1. CONTENT EXPERTS

#### **CONTENT EXPERTS**

- Monisha Sharma (UW: Global Health & Epidemiology)
- Jared Baeten (UW: Allergy and Infectious Disease & Global Health; Gilead Science, Vice President)
- Renee Heffron (UW: Global Health; UAB: CFAR Director)
- Katrina Ortblad (UW: Global Health)
- Andy Stergachis (UW: Global Health, Pharmacy, Epidemiology, Health Metrics, Health Systems)
- Anjali Sharma (UW: Global Health; Center for Infectious Disease Research in Zambia)
- Gabrielle O'Malley (UW: Global Health)
- Sarah Gimbel (UW: Global Health, Center for Global Health Nursing)
- Kenneth Ngure (UW: Global Health)
- Kenneth Mugwanya (UW: Global Health & Epidemiology)
- Connie Celum (UW: Global Health, Epidemiology, Allergy and Infectious Diseases)

#### COUNTRY-LEVEL EXPERTS

- Uganda
  - Timothy Muwonge (Makerere University)
  - Andrew Mujugira (UW: Global Health & Makerere University)
- Mozambique
  - Maria de Fátima Cuembelo (UW: Global Health & Epidemiology)
- Zambia
  - Margaret Kasaro (UNC: Global Health & Zambia Institute for Global Health)
- Eswatini
  - Harriette Nuwagaba-Biribonwoha (Columbia University: Research Director of ICAP in Eswatini)
- Zimbabwe
  - Nyaradzo Mgodi (Zimbabwe; University of Zimbabwe)

### **2. SEARCH STRINGS**

Search String	Results
Broadest Search (("pre exposure prophylaxis"[Title/Abstract] OR "prep"[Title/Abstract] OR "hiv prophylaxis"[Title/Abstract]) AND ("pharmacy"[Title/Abstract] OR "pharmacies"[Title/Abstract] OR "pharmacist"[Title/Abstract] OR "pharmacy-delivered"[Title/Abstract]))	139
Specifying Injectable PrEP/CAB-LA ("CAB-LA"[Title/Abstract] OR "injectable pre exposure prophylaxis"[Title/Abstract] OR "injectable prep"[Title/Abstract] OR "injectable hiv prophylaxis"[Title/Abstract] OR "cabotegravir"[Title/Abstract]) AND ("pharmacy"[Title/Abstract] OR "pharmacies"[Title/Abstract] OR "pharmacist"[Title/Abstract] OR "pharmacy-delivered"[Title/Abstract])	7
Including Country Names ("pre exposure prophylaxis"[Title/Abstract] OR "prep"[Title/Abstract] OR "hiv prophylaxis"[Title/Abstract]) AND ("pharmacy"[Title/Abstract] OR "pharmacies"[Title/Abstract] OR "pharmacist"[Title/Abstract] OR "pharmacy-delivered"[Title/Abstract]) AND ("Tanzania"[Title/Abstract] OR "Nigeria"[Title/Abstract] OR "Ghana"[Title/Abstract] OR "Uganda"[Title/Abstract] OR "Mozambique"[Title/Abstract] OR "Zambia"[Title/Abstract] OR "Eswatini"[Title/Abstract] OR "Swazil and"[Title/Abstract]OR "Zimbabwe"[Title/Abstract] OR "Ivory Coast"[Title/Abstract] OR "Côte d'Ivoire"[Title/Abstract] OR "Cameroon"[Title/Abstract])	0
Broadest Search (("pharmacists"[Title/Abstract] OR "pharmacy"[Title/Abstract]) AND ("Tanzania"[Title/Abstract] OR "Nigeria"[Title/Abstract] OR "Ghana"[Title/Abstract] OR "Uganda"[Title/Abstract] OR "Mozambique"[Title/Abstract] OR "Zambia"[Title/Abstract] OR "Eswatini"[Title/Abstract] OR "Swaziland"[Title/Abstract] OR "Zimbabwe"[Title/Abstract] OR "Ivory Coast"[Title/Abstract] OR "Cote d'Ivoire"[Title/Abstract] OR "Cameroon"[Title/Abstract]) AND (2006:2023[pdat])	34
Including Delivery ("pharmacists"[Title/Abstract] OR "pharmacy"[Title/Abstract]) AND ("deliver"[Title/Abstract] OR "delivery"[Title/Abstract]) AND ("united states"[Title/Abstract] OR "US"[Title/Abstract]) AND ("Tanzania"[Title/Abstract] OR "Nigeria"[Title/Abstract] OR "Ghana"[Title/Abstract] OR "Uganda"[Title/Abstract] OR "Mozambique"[Title/Abstract] OR "Zambia"[Title/Abstract] OR "Eswatini"[Title/Abstract] OR "Swaziland"[Title/Abstract] OR "Zimbabwe"[Title/Abstract] OR "Ivory Coast"[Title/Abstract] OR "Cote d'Ivoire"[Title/Abstract] OR "Cameroon"[Title/Abstract])	5
Including Prescription ("pharmacists"[Title/Abstract] OR "pharmacy"[Title/Abstract]) AND ("prescription"[Title/Abstract] OR "prescribe"[Title/Abstract]) AND ("united states"[Title/Abstract] OR "US"[Title/Abstract]) AND ("Tanzania"[Title/Abstract] OR "Nigeria"[Title/Abstract] OR "Ghana"[Title/Abstract] OR "Uganda"[Title/Abstract] OR "Mozambique"[Title/Abstract] OR "Zambia"[Title/Abstract] OR "Eswatini"[Title/Abstract] OR "Swaziland"[Title/Abstract] OR "Zimbabwe"[Title/Abstract] OR "Ivory Coast"[Title/Abstract] OR "Cote d'Ivoire"[Title/Abstract] OR "Cameroon"[Title/Abstract])	4



### Zimbabwe

#### **HIV Epidemiology**

https://www.prepwatch.org/wp-content/uploads/2022/11/Zimbabwe-COP-2022.pdf

https://zw.usembassy.gov/national-hiv-survey-zimphia-2020-resultsindicate-zimbabwe-is-on-track-to-achieve-hiv-epidemic-control-by-2030/

#### PrEP Overview

https://www.prepwatch.org/wp-content/uploads/2022/11/Zimbabwe-COP-2022.pdf

#### Stakeholders

https://www.zamra.co.zm/#:~:text=Zambia%20Medicines%20Regulator y%20Authority%20(ZAMRA)

#### National Strategies

https://www.nac.org.zm/sites/default/files/publications/NASF%202017 %20-%202021.pdf

#### Funding

https://www.prepwatch.org/wp-content/uploads/2022/11/Zimbabwe-COP-2022.pdf

#### **PrEP Policies**

https://bmjopen.bmj.com/content/11/7/e047017 https://pubmed.ncbi.nlm.nih.gov/34244265/

#### Pharmacy Landscape https://pdf.usaid.gov/pdf\_docs/PA00W73P.pdf

https://www.lusakatimes.com/2022/11/07/masebo-issues-directive-toall-public-health-facilities-not-to-host-any-private-pharmacy-orlaboratory/

https://www.fhi360.org/sites/default/files/media/documents/epic-project-strategic-guide-scale-up.pdf

### Uganda

#### **HIV Epidemiology**

https://www.prepwatch.org/wp-

content/uploads/2022/11/Uganda-COP-2022.pdf

https://phia.icap.columbia.edu/wpcontent/uploads/2022/08/UPHIA-Summary-Sheet-2020.pdf

#### **PrEP** Overview

#### https://www.nda.or.ug/

https://www.voaafrica.com/a/uganda-approves-injectablehiv-drug-amid-increasing-infections-

/6893766.html#:~:text=Üganda%20has%20approved%20t he%20long,Uganda%2C%20according%20to%20official% 20data.

#### Stakeholders

https://www.prepwatch.org/wpcontent/uploads/2022/11/Uganda-COP-2022.pdf

#### National Strategies

https://www.prepwatch.org/wp-

content/uploads/2022/11/Uganda-COP-2022.pdf

Funding

https://www.prepwatch.org/wp-

content/uploads/2022/11/Uganda-COP-2022.pdf

#### **PrEP Policies**

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8843287/ https://prepwatch.org/wp-

content/uploads/2022/07/UgandaHIVGuidelines2018.doc https://www.frontiersin.org/articles/10.3389/fpubh.2022.65 8826/full

#### Pharmacy Landscape

https://www.fic.nih.gov/News/GlobalHealthMatters/marchapril-2022/Pages/fogarty-fellow-investigates-nurse-led-PrEP-delivery-uganda.aspx

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713199/ https://www.independent.co.ug/uganda-will-not-dispenseprep-over-the-counter-minister/

https://www.psi.org/project/self-care/a-spotlight-onstrengthening-hiv-self-testing-in-the-private-sector-ships/



#### Continued

	https://www.fhi360.org/sites/default/files/media/docu
	ments/epic-art-ddd-covid-19.pdf
	http://www.times.co.sz/news/128789-another-drugs-
	shortage-hits-
	eswatini.html#:~:text=A%20majority%20of%20public
	%20health,known%20for%20fighting%20bacterial%2
	Oinfections.
	Pharmacist Capabilities
	https://publications.jsi.com/JSIInternet/Inc/Common/_
r	download pub.cfm?id=22807&lid=3
	https://gh.bmj.com/content/7/1/e007312
	Case Studies
	https://www.scirp.org/journal/paperinformation.aspx?
	paperid=44170
	https://pubmed.ncbi.nlm.nih.gov/33865471/
	https://www.fhi360.org/sites/default/files/media/docu
	ments/epic-project-strategic-guide-scale-up.pdf
	Other Key Information
	https://www.frontiersin.org/articles/10.3389/frph.2021.
	684717/full
	https://fpoptions.org/wp-content/uploads/AC-ICFP-
	premeeting-PATH-2019.pdf
	Consulted Content Experts

Nyaradzo Mgodi (Zimbabwe; University of Zimbabwe)

#### Pharmacist Capabilities

https://substanceabusepolicy.biomedcentral.com/articles/1 0.1186/s13011-020-00261-x

https://bmchealthservres.biomedcentral.com/articles/10.11 86/s12913-018-3343-z

https://uniph.go.ug/assessment-of-oral-pre-exposureprophylaxis-eligibility-and-use-among-persons-atsubstantial-risk-of-hiv-acquisition-uganda-2017-2021/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5878078/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7846921/

#### Case Studies

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7208546/ https://www.thelancet.com/journals/eclinm/article/PIIS2589 -5370(22)00341-8/fulltext

https://www.psi.org/project/self-care/a-spotlight-onstrengthening-hiv-self-testing-in-the-private-sector-ships/ https://www.frontiersin.org/articles/10.3389/fpubh.2022.65 8826/full

#### Other Key Information

https://bmcinfectdis.biomedcentral.com/articles/10.1186/s1 2879-022-07398-z

https://pubmed.ncbi.nlm.nih.gov/36066762/

https://www.prepwatch.org/resources/dapivirine-ring-introconsiderations-uganda/

#### https://link.springer.com/article/10.1007/s10461-021-03205-z

https://fpoptions.org/wp-content/uploads/AC-ICFPpremeeting-PATH-2019.pdf

#### Consulted Content Experts

Andrew Mujugira (UW: Global Health & Makerere University)

Timothy Muwonge (Makerere University)

### Eswatini

#### HIV Epidemiology

- https://www.prepwatch.org/wpcontent/uploads/2022/11/Eswatini-COP-2022.pdf
- https://www.beintheknow.org/understandinghiv-epidemic/data/glance-hiv-eswatini

#### PrEP Overview

- https://onlinelibrary.wiley.com/doi/10.1002/jia 2.25408
- https://www.prepwatch.org/wpcontent/uploads/2022/11/Eswatini-COP-2022.pdf
- Stakeholders
  - https://www.prepwatch.org/wpcontent/uploads/2022/05/PROMISE\_Output\_ 1.1\_ESWATINI\_Dapivirine\_Ring\_Consultatio n\_FINAL.pdf
  - https://www.ncbi.nlm.nih.gov/pmc/articles/PM C8517741/#CIT0022

#### National Strategies

- http://www.healthpolicyplus.com/PrEPitTool.c fm
- Funding
  - http://www.healthpolicyplus.com/PrEPitTool.c fm

# PrEP Policies https://

https://prepwatch.org/wpcontent/uploads/2022/03/Eswatini-National-HIVAIDS-Guidelines-2018-2023.pdf

#### • Pharmacy Landscape

- https://researchspace.ukzn.ac.za/handle/104 13/19501
- http://www.rrfa.co.za/wp-

# Mozambique

#### HIV Epidemiology

https://www.prepwatch.org/wp-content/uploads/2022/11/Mozambique-COP-2022.pdf

- PrEP Overview
  - https://www.prepwatch.org/wp-content/uploads/2022/11/Mozambique-COP-2022.pdf
- Stakeholders
  - https://nmra.gov.lk/index.php?lang=en

#### National Strategies

- https://www.prepwatch.org/wp-content/uploads/2022/11/Mozambique-COP-2022.pdf
- Funding
  - https://www.prepwatch.org/wp-content/uploads/2022/11/Mozambique-COP-2022.pdf
- https://
   PrEP Policies
  - https://www.prepwatch.org/wp-content/uploads/2022/11/Mozambique-COP-2022.pdf

#### Pharmacy Landscape

- https://cquin.icap.columbia.edu/wp-content/uploads/2022/12/B23.-DD-of-ART-private-pharmacies\_Follow-up-of-patients-in-Mozambique-1.pdf
- Pharmacist Capabilities
  - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6805650/#:~:text=ln%20Mozambique%2C%20all%20medicines%20purchased,doctors%2C%2 0physicians%20or%20qualified%20HCP.
  - o https://www.nature.com/articles/s41599-019-0385-8
  - https://www.fip.org/file/5176

#### Case Studies

- o https://www.fhi360.org/sites/default/files/media/documents/epic-ddd-mozambique.pdf
- https://iop.harvard.edu/sites/default/files/sources/program/IOP\_Policy\_Program\_2019\_HIV\_AIDS\_prevention\_treatment\_public\_private\_partne rships.pdf
- Consulted Content Experts
  - Maria de Fátima Cuembelo (UW: Global Health & Epidemiology)

#### Continued

- https://www.who.int/publicationsdetail-redirect/9789240018303
- https://www.ncbi.nlm.nih.gov/pmc/artic les/PMC8517741

### Pharmacist Capabilities

- http://www.times.co.sz/news/135735almost-50-of-eswatini-pharmaciesoperating-illegally.html
- https://commonwealthpharmacycpd.or g/member-organisations/kingdom-ofeswatini-pharmacy-association/
- https://www.ncbi.nlm.nih.gov/pmc/artic les/PMC7347100/

#### Case Studies

- https://journals.lww.com/aidsonline/Ful ltext/2018/07170/Preference\_for\_injec table\_over\_oral\_HIV.20.aspx
- https://cquin.icap.columbia.edu/wpcontent/uploads/2022/07/Final\_Policy-Guidelines-for-Eswatini-Differentiated-Service-Delivery.pdf
- https://polisci.rutgers.edu/publications/ occasional-paper-series/358occasional-paper-13-kate-ann-bracehiv-aids-policies-and-strategies-in-thekingdom-of-eswatini/file

# Nigeria

#### • HIV Epidemiology

- https://www.prepwatch.org/wp-content/uploads/2022/11/Nigeria-COP-2022.pdf
  - https://www.cia.gov/the-world-factbook/countries/nigeria
- https://v
   PrEP Overview
  - https://www.prepwatch.org/wp-content/uploads/2022/11/Nigeria-COP-2022.pdf
- Stakeholders
   https://www.selectropy.com/se
  - https://www.nafdac.gov.ng/drugs/drug-guidelines/
- National Strategies
  - o https://prepwatch.org/resources/nigeria-national-hiv-aids-strategic-plan-2017-21/
- Funding
  - https://www.prepwatch.org/wp-content/uploads/2022/11/Nigeria-COP-2022.pdf
  - PrEP Policies
    - https://www.prepwatch.org/resources/nigeria-cop-2022/

#### Pharmacy Landscape

- o https://www.usaid.gov/global-health/health-areas/hiv-and-aids/technical-areas/differentiated-service-delivery
- o https://www.fhi360.org/sites/default/files/media/documents/epic-project-strategic-guide-scale-up.pdf
- https://www.fhi360.org/sites/default/files/media/documents/epic-art-ddd-covid-19.pdf
- Pharmacist Capabilities
  - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360771/#b0135
    - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360771/
- Case Studies
  - https://www.fhi360.org/sites/default/files/media/documents/epic-project-strategic-guide-scale-up.pdf
  - https://www.fhi360.org/sites/default/files/media/documents/epic-art-ddd-covid-19.pdf

# Zambia

#### HIV Epidemiology

- https://www.prepwatch.org/wpcontent/uploads/2022/11/Zambia-COP-2022.pdf
- PrEP Overview
  - https://www.prepwatch.org/wpcontent/uploads/2022/11/Zambia-COP-2022.pdf
- Stakeholders
  - https://www.zamra.co.zm/#:~:text=Zambia%20 Medicines%20Regulatory%20Authority%20(Z AMRA)
- National Strategies
  - https://www.nac.org.zm/sites/default/files/publi cations/NASF%202017%20-%202021.pdf
- Funding
  - https://www.nac.org.zm/sites/default/files/publi cations/NASF%202017%20-%202021.pdf
  - https://www.ncbi.nlm.nih.gov/pmc/articles/PM C8273462/
- PrEP Policies
  - https://bmjopen.bmj.com/content/11/7/e04701
     7
  - https://pubmed.ncbi.nlm.nih.gov/34244265/

#### Pharmacy Landscape

- https://pdf.usaid.gov/pdf\_docs/PA00W73P.pdf
- https://www.lusakatimes.com/2022/11/07/mas ebo-issues-directive-to-all-public-healthfacilities-not-to-host-any-private-pharmacy-orlaboratory/
- https://www.fhi360.org/sites/default/files/media
   /documents/epic-project-strategic-guide-scaleup.pdf

#### Continued

https://www.fhi360.org/sites/default/files/media/do cuments/epic-art-ddd-covid-19.pdf

 http://www.times.co.sz/news/128789-anotherdrugs-shortage-hitseswatini.html#:~:text=A%20majority%20of%20pu blic%20health,known%20for%20fighting%20bacte rial%20infections.

#### Pharmacist Capabilities

- https://publications.jsi.com/JSIInternet/Inc/Co mmon/\_download\_pub.cfm?id=22807&lid=3
- https://gh.bmj.com/content/7/1/e007312

#### Case Studies

- https://www.scirp.org/journal/paperinformatio n.aspx?paperid=44170
- https://pubmed.ncbi.nlm.nih.gov/33865471/
- https://www.fhi360.org/sites/default/files/medi a/documents/epic-project-strategic-guidescale-up.pdf
- Other Key Information
  - https://www.frontiersin.org/articles/10.3389/fr ph.2021.684717/full
  - https://fpoptions.org/wp-content/uploads/AC-ICFP-premeeting-PATH-2019.pdf

#### Consulted Content Experts

Margaret Kasaro (UNC: Global Health & Zambia Institute for Global Health)

### Tanzania

Tanzan	lia
<ul> <li>HIV Epidemiology         <ul> <li>https://www.prepwatch.org/wp-content/uploads/2022/11/Tanzania-COP.2022.pdf</li> </ul> </li> <li>PrEP Overview         <ul> <li>https://www.prepwatch.org/countries/tanzania/</li> </ul> </li> <li>Stakeholders         <ul> <li>https://www.tmda.go.tz/</li> </ul> </li> <li>National Strategies             <ul> <li>https://prepwatch.org/wp-content/uploads/2022/03/Tanzania-National-HIVAIDS-Guidelines-2019.pdf</li> </ul> </li> <li>Funding             <ul> <li>https://www.prepwatch.org/wp-content/uploads/2022/11/Tanzania-COP.2022.pdf</li> </ul> </li> <li>PrEP Policies             <ul> <li>https://www.prepwatch.org/wp-content/uploads/2022/11/Tanzania-COP.2022.pdf</li> </ul> </li> <li>PrEP Policies             <ul> <li>https://www.prepwatch.org/wp-content/uploads/2022/11/Tanzania-COP.2022.pdf</li> <li>PrEP Policies                 <ul> <li>https://ournals.plos.org/globalpublichealth/article?id=10.1371/journal.pgph.0000981</li> <li>https://apps.who.int/iris/rest/bitstreams/1418002/retrieve</li> <li>bttps://decumpate.word/dop/88</li> <li>https://apps.who.int/iris/rest/bitstreams/141800</li> <li>bttps://apps.who.int/iris/rest/bitstreams/141800</li> <li>bttps://documpate.word/dop/88</li></ul></li></ul></li></ul>	<ul> <li>Continued         <ul> <li>Tanzania Food and Drug Authority. Annual Report. Dar es Salaam: TFDA; 2004.</li> <li>The United Republic of Tanzania. The Tanzania Food, Drugs and Cosmetics Act. Dar es, Salaam: TFDA; 2003.</li> </ul> </li> <li>Pharmacist Capabilities         <ul> <li>https://www.ijpsonline.com/articles/dispensing -practice-of-prescribed-medicines-in-the-private-pharmacies-in-urban-areas-of-tanzania.html#5</li> <li>https://aidsrestherapy.biomedcentral.com/articles/10.1186/s12981-021-00343-1</li> <li>https://pubmed.ncbi.nlm.nih.gov/20208262/</li> </ul> </li> <li>Case Studies         <ul> <li>https://www.state.gov/wp-content/uploads/2022/09/Tanzania-COP22-SDS.pdf</li> <li>https://www.pc.go.tz/addo/#:~:text=ADDO%2 Ostands%20for%20Accredited%20Drug,wher e%20there%20were%20no%20pharmacies.</li> </ul> </li> <li>Other Key Information         <ul> <li>https://www.prepwatch.org/resources/dapiviri ne-ring-early-intro-considerations-tanzania/</li> </ul> </li> </ul>
<ul> <li>https://documents.worldbank.org/curated/en/88 8021468132272587/pdi/Private-health-sector assessment-in-Tanzania.cdf</li> </ul>	
<ul> <li>HIV Epidemiology         <ul> <li>https://www.prepwatch.org/wp-content/uploads/2022/11/West-Africa-Region-ROP-2022.pdf</li> </ul> </li> <li>PrEP Overview         <ul> <li>https://www.prepwatch.org/wp-content/uploads/2022/11/West-Africa-Region-ROP-2022.pdf</li> </ul> </li> <li>Stakeholders         <ul> <li>http://www.fdaghana.gov.gh/</li> <li>https://www.state.gov/wp-content/uploads/2022/09/West-Africa-Region-ROP22-SDS.pdf</li> </ul> </li> <li>National Strategies         <ul> <li>https://www.prepwatch.org/wp-content/uploads/2022/11/West-Africa-Region-ROP22-SDS.pdf</li> </ul> </li> </ul>	<ul> <li>Pharmacist Capabilities         <ul> <li>https://bmcmededuc.biomedcentral.com/articles/10.1186/s12909-020-02393-x</li> <li>https://www.aidsmap.com/about-hiv/post-exposure-prophylaxis-pep#:~:text=PEP%20is%20available% 20from%20sexual%20health%20clinicss%20and%20accident%20%26%20emergency%20departments.</li> <li>https://www.guttmacher.org/journals/ipsrh/2014/03/injectable-contraceptive-sales-licensed-chemical-seller-shops-ghana-access</li> <li>https://www.prepwatch.org/resources/ghana-national-hiv-aids-strategic-plan-</li> </ul> </li> </ul>
<ul> <li>2022.pdf</li> <li>Funding         <ul> <li>https://www.prepwatch.org/resources/ghana-national-hivaids-strategic-plan-2021-25/</li> <li>https://www.prepwatch.org/resources/ghana-national-hivaids-policy-2019/</li> </ul> </li> <li>PrEP Policies         <ul> <li>https://www.state.gov/wp-content/uploads/2022/09/West-Africa-Region-ROP22-SDS.pdf</li> </ul> </li> <li>Pharmacy Landscape         <ul> <li>https://joppp.biomedcentral.com/articles/10.1186/s40545-</li> </ul> </li> </ul>	2021-25/ • https://pubmed.ncbi.nlm.nih.gov/11358 916/ • Case Studies • https://www.fhi360.org/sites/default/files/ media/documents/resource-epic-ghana- success-story.pdf • Other Key Information • https://www.ncbi.nlm.nih.gov/pmc/articl es/PMC6980967/ • https://journals.lww.com/md- journal/Fulltext/2022/02040/Willingnes
021-00363-2 https://www.sciencedirect.com/science/article/pii/S02779536	s_to_take_and_ever_use_of_pre_exp

- https://www.sciencedirect.com/science/article/pii/S02779536 19303545
- https://openknowledge.worldbank.org/handle/10986/28117
- https://go.gale.com/ps/i.do?id=GALE%7CA600204230&sid= googleScholar&v=2.1&it=r&linkaccess=abs&issn=20523211 &p=HRCA&sw=w&userGroupName=anon%7E4b8ed36c
- https://akzente.giz.de/en/voices/covid-ghana



osure.54.aspx